Janux Therapeutics, Inc.

US$17.63As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:JANXHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (6.28%)
Div yield —
ROE (10.58%)
Biotechnology
Beta (5Y) 2.39
PE TTM —
TSR TTM (38.59%)
Mkt cap US$1.079B
ROIC (9.03%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$23
28.53%
(33.84%)
Hold 3|6|4|7|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.28
0.27
0.29
0.30
15.38%
4.04%
0.10%
5.68%
Revenue$M
82.44
84.76
84.07
82.57
7.42%
12.14%
12.25%
5.37%
Peers (US$1.079B)
Cap (US$)
PE
1.060B
—
Capital
TTM
5Y
10Y
Leveragex
1.189
0.820
0.595
EBIT/Intx
2.330
7.178
6.698
Own earn%
(20.91)
193.93
178.70
Sh yield%
17.46
40.64
37.50
Owners
Insiders/Inst%
2.26
41.23
Short interest%
5.37
SBC / revenue%
3.16
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
27–34
$1 testx
0.2
Incr. ROIC%
3